Short Interest in HCW Biologics Inc. (NASDAQ:HCWB) Drops By 10.9%

HCW Biologics Inc. (NASDAQ:HCWB) was the recipient of a significant decrease in short interest during the month of November. As of November 30th, there was short interest totalling 128,900 shares, a decrease of 10.9% from the November 15th total of 144,700 shares. Approximately 0.7% of the company’s shares are sold short. Based on an average trading volume of 9,020,000 shares, the short-interest ratio is presently 0.0 days.

HCW Biologics Trading Down 1.7 %

Shares of NASDAQ HCWB traded down $0.01 during trading hours on Tuesday, hitting $0.35. The company’s stock had a trading volume of 134,395 shares, compared to its average volume of 2,463,619. The business has a 50-day simple moving average of $0.50 and a 200-day simple moving average of $0.60. The stock has a market cap of $13.24 million, a price-to-earnings ratio of -0.35 and a beta of 0.88. The company has a debt-to-equity ratio of 0.95, a quick ratio of 0.07 and a current ratio of 0.07. HCW Biologics has a 12 month low of $0.28 and a 12 month high of $2.52.

HCW Biologics Company Profile

HCW Biologics Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and age-related diseases in the United States. The company's lead products include HCW9218, which is in Phase 1 clinical chemo-refractory/chemo-resistant solid tumors with pancreatic, ovarian, breast, prostate, and colorectal cancers, as well as Phase 2 clinical trial with metastatic advanced stage ovarian cancer patients; and HCW9302 for autoimmune and proinflammatory diseases, such as alopecia areata diseases.